Loading candles…
Jagsonpal Pharmaceuticals Ltd, incorporated in 1978, operates in the pharmaceutical industry with a focus on manufacturing and trading pharmaceutical products and active pharmaceutical ingredients. The company primarily serves the Indian market and concentrates on women's health and pain management through a niche-focused approach. Over time, Jagsonpal has established leadership in specific therapeutic molecules and expanded its portfolio via organic product launches and strategic acquisitions. Initially a family-run business, it transitioned to professional management after Infinity Holdings acquired a significant stake in June 2022.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 27 Apr 2026 |
| Buyback | To consider buyback for equity shares | 12 Mar 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 21 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 3 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 26 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend, if any | 6 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.